U.S. premarket movers rise on analyst upgrades, report-driven deal optimism

Traders Union
All News
Financial News
US premarket movers rise

Highlights

Salesforce surges 4% premarket after Bank of America double-upgrades the stock, stating AI will increase reliance on the company's software.
First Solar, Biogen, IREN, SLM, and Mattel gain 1–5.3% after broker upgrades and a report on IREN’s cloud deal with Anthropic increase optimism.
Upgrades and deal speculation drive sector rotation, with investors responding positively to perceived valuation opportunities and prospective catalysts in premarket trading.

Upgrades and report lift early trading

As reported by CNBC, a cluster of premarket gainers is emerging as broker upgrades and a media report reshape near-term sentiment across software, solar, biotechnology, consumer goods and student lending.

Salesforce rises 4% after Bank of America double upgrades the stock to buy from underperform, arguing that artificial intelligence should not disrupt the company but instead "deepen dependence" on its software. First Solar gains 2.4% after Truist upgrades the solar company to buy from hold, citing confidence in growth, strong market demand over the coming years and the group's pricing power.

Biogen adds 2% after JPMorgan upgrades the biotech stock to overweight from neutral. The firm points to several clinical readouts in 2027 as potential catalysts for the company.

Australia-based IREN jumps 5.3% after The Information reports that the company has quietly signed a multiyear cloud computing deal with Anthropic. The company says it owns and operates with 100% renewable energy.

Sector signals shape investor focus

SLM advances 2% after Morgan Stanley upgrades the education loan administrator to overweight from equal weight. The bank says the stock, which is down 15% year to date, represents a buying opportunity because of its valuation.

Mattel rises more than 1% after Seaport upgrades the toymaker to buy from neutral. The research firm says speculation around a potential takeover is prompting investors to reassess toy stocks and recognize value that may not be fully reflected in share prices.

The moves indicate that premarket trading remains highly responsive to sell-side rating changes and deal-related headlines, particularly when they reinforce expectations for demand, pricing strength or future catalysts in company-specific stories.

Biogen’s JPMorgan upgrade to overweight outlined a catalyst-rich stretch of upcoming trial data that could improve sentiment and support a higher valuation. Our earlier article highlighted key pipeline milestones through 2027—especially felzartamab Phase 3 data and other readouts tied to Leqembi and litifilimab—that the bank sees as potential drivers of investor confidence.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.